These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

563 related articles for article (PubMed ID: 33128190)

  • 21. Screening of
    Montalban G; Bonache S; Moles-Fernández A; Gisbert-Beamud A; Tenés A; Bach V; Carrasco E; López-Fernández A; Stjepanovic N; Balmaña J; Diez O; Gutiérrez-Enríquez S
    J Med Genet; 2019 Feb; 56(2):63-74. PubMed ID: 30472649
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Familial history and prevalence of BRCA1, BRCA2 and TP53 pathogenic variants in HBOC Brazilian patients from a public healthcare service.
    Matta BP; Gomes R; Mattos D; Olicio R; Nascimento CM; Ferreira GM; Brant AC; Boroni M; Furtado C; Lima V; Moreira MÂM; Dos Santos ACE
    Sci Rep; 2022 Nov; 12(1):18629. PubMed ID: 36329109
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Whole-exome sequencing of non-BRCA1/BRCA2 mutation carrier cases at high-risk for hereditary breast/ovarian cancer.
    Felicio PS; Grasel RS; Campacci N; de Paula AE; Galvão HCR; Torrezan GT; Sabato CS; Fernandes GC; Souza CP; Michelli RD; Andrade CE; Barros BDF; Matsushita MM; Revil T; Ragoussis J; Couch FJ; Hart SN; Reis RM; Melendez ME; Tonin PN; Carraro DM; Palmero EI
    Hum Mutat; 2021 Mar; 42(3):290-299. PubMed ID: 33326660
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of the functional impact of germline BRCA1/2 variants located in non-coding regions in families with breast and/or ovarian cancer predisposition.
    Dos Santos ES; Caputo SM; Castera L; Gendrot M; Briaux A; Breault M; Krieger S; Rogan PK; Mucaki EJ; Burke LJ; ; Bièche I; Houdayer C; Vaur D; Stoppa-Lyonnet D; Brown MA; Lallemand F; Rouleau E
    Breast Cancer Res Treat; 2018 Apr; 168(2):311-325. PubMed ID: 29236234
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Frequency of mutations in BRCA genes and other candidate genes in high-risk probands or probands with breast or ovarian cancer in the Czech Republic.
    Riedlova P; Janoutova J; Hermanova B
    Mol Biol Rep; 2020 Apr; 47(4):2763-2769. PubMed ID: 32180084
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel candidates of pathogenic variants of the BRCA1 and BRCA2 genes from a dataset of 3,552 Japanese whole genomes (3.5KJPNv2).
    Tokunaga H; Iida K; Hozawa A; Ogishima S; Watanabe Y; Shigeta S; Shimada M; Yamaguchi-Kabata Y; Tadaka S; Katsuoka F; Ito S; Kumada K; Hamanaka Y; Fuse N; Kinoshita K; Yamamoto M; Yaegashi N; Yasuda J
    PLoS One; 2021; 16(1):e0236907. PubMed ID: 33428613
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Variants of cancer susceptibility genes in Korean BRCA1/2 mutation-negative patients with high risk for hereditary breast cancer.
    Park JS; Lee ST; Nam EJ; Han JW; Lee JY; Kim J; Kim TI; Park HS
    BMC Cancer; 2018 Jan; 18(1):83. PubMed ID: 29338689
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prioritizing Variants in Complete Hereditary Breast and Ovarian Cancer Genes in Patients Lacking Known BRCA Mutations.
    Caminsky NG; Mucaki EJ; Perri AM; Lu R; Knoll JH; Rogan PK
    Hum Mutat; 2016 Jul; 37(7):640-52. PubMed ID: 26898890
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Germline Mutation in 1338 BRCA-Negative Chinese Hereditary Breast and/or Ovarian Cancer Patients: Clinical Testing with a Multigene Test Panel.
    Kwong A; Shin VY; Chen J; Cheuk IWY; Ho CYS; Au CH; Chan KKL; Ngan HYS; Chan TL; Ford JM; Ma ESK
    J Mol Diagn; 2020 Apr; 22(4):544-554. PubMed ID: 32068069
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BRCA1/2 variants of unknown significance in hereditary breast and ovarian cancer (HBOC) syndrome: Looking for the hidden meaning.
    Fanale D; Pivetti A; Cancelliere D; Spera A; Bono M; Fiorino A; Pedone E; Barraco N; Brando C; Perez A; Guarneri MF; Russo TDB; Vieni S; Guarneri G; Russo A; Bazan V
    Crit Rev Oncol Hematol; 2022 Apr; 172():103626. PubMed ID: 35150867
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BRCA1 and BRCA2 Germline Mutation Analysis in Hereditary Breast/Ovarian Cancer Families from the Aures Region (Eastern Algeria): First Report.
    Mehemmai C; Cherbal F; Hamdi Y; Guedioura A; Benbrahim W; Bakour R; Abdelhak S
    Pathol Oncol Res; 2020 Apr; 26(2):715-726. PubMed ID: 30715675
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence of BRCA1 and BRCA2 pathogenic and likely pathogenic variants in non-selected ovarian carcinoma patients in Brazil.
    Cotrim DP; Ribeiro ARG; Paixão D; de Queiroz Soares DC; Jbili R; Pandolfi NC; Cezana C; de Cássia Mauro C; Mantoan H; Bovolim G; de Brot L; Torrezan GT; Carraro DM; Baiocchi G; da Cruz Formiga MN; da Costa AABA
    BMC Cancer; 2019 Jan; 19(1):4. PubMed ID: 30606148
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular characterization and clinical interpretation of BRCA1/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical-pathological features in BRCA carriers and non-carriers.
    Gabaldó Barrios X; Sarabia Meseguer MD; Marín Vera M; Sánchez Bermúdez AI; Macías Cerrolaza JA; Sánchez Henarejos P; Zafra Poves M; García Hernández MR; Cuevas Tortosa E; Aliaga Baño Á; Castillo Guardiola V; Martínez Hernández P; Tovar Zapata I; Martínez Barba E; Ayala de la Peña F; Alonso Romero JL; Noguera Velasco JA; Ruiz Espejo F
    Fam Cancer; 2017 Oct; 16(4):477-489. PubMed ID: 28477318
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interdisciplinary risk counseling for hereditary breast and ovarian cancer: real-world data from a specialized center.
    Zang B; Helms M; Besch L; Kalmbach N; Stegen S; Blohmer JU; Speiser D
    Arch Gynecol Obstet; 2023 May; 307(5):1585-1592. PubMed ID: 36307613
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers.
    Cragun D; Weidner A; Tezak A; Clouse K; Pal T
    Breast Cancer Res Treat; 2020 Jul; 182(2):421-428. PubMed ID: 32445176
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of Germline Variants in 450 Breast/Ovarian Cancer Families with a Multi-Gene Panel Including Coding and Regulatory Regions.
    Guglielmi C; Scarpitta R; Gambino G; Conti E; Bellè F; Tancredi M; Cervelli T; Falaschi E; Cosini C; Aretini P; Congregati C; Marino M; Patruno M; Pilato B; Spina F; Balestrino L; Tenedini E; Carnevali I; Cortesi L; Tagliafico E; Tibiletti MG; Tommasi S; Ghilli M; Vivanet C; Galli A; Caligo MA
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299313
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased incidence of pathogenic variants in ATM in the context of testing for breast and ovarian cancer predisposition.
    Macquere P; Orazio S; Bonnet F; Jones N; Bubien V; Chiron J; Lafon D; Barouk-Simonet E; Tinat J; Venat-Bouvet L; Gesta P; Longy M; Sevenet N
    J Hum Genet; 2022 Jun; 67(6):339-345. PubMed ID: 35017683
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The identification of pathogenic variants in BRCA1/2 negative, high risk, hereditary breast and/or ovarian cancer patients: High frequency of FANCM pathogenic variants.
    Schubert S; van Luttikhuizen JL; Auber B; Schmidt G; Hofmann W; Penkert J; Davenport CF; Hille-Betz U; Wendeburg L; Bublitz J; Tauscher M; Hackmann K; Schröck E; Scholz C; Wallaschek H; Schlegelberger B; Illig T; Steinemann D
    Int J Cancer; 2019 Jun; 144(11):2683-2694. PubMed ID: 30426508
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of hereditary breast and ovarian cancer germline variants in Granada (Spain): NGS perspective.
    Molina-Zayas M; Garrido-Navas C; García-Puche JL; Barwell J; Pedrinaci S; Atienza MM; García-Linares S; de Haro-Muñoz T; Lorente JA; Serrano MJ; Poyatos-Andújar A
    Mol Genet Genomics; 2022 May; 297(3):859-871. PubMed ID: 35451682
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BRCA1 and BRCA2 germline mutation analysis from a cohort of 1267 patients at high risk for breast cancer in Brazil.
    Mazzonetto P; Milanezi F; D'Andrea M; Martins S; Monfredini PM; Dos Santos Silva J; Perrone E; Villela D; Schnabel B; Nakano V; Palmero EI; Braggio E; Cavalcanti TL; Guida G; Migliavacca MP; Scapulatempo-Neto C; Zalcberg I
    Breast Cancer Res Treat; 2023 May; 199(1):127-136. PubMed ID: 36881271
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.